Connect with us

Top Biotech Penny Stocks On Robinhood To Watch This Week

Biotech stocks take spotlight as sector reaches 1 month high.
The post Top Biotech Penny Stocks On Robinhood To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Published

on

Penny stocks are just one of the hot trends in the stock market this week. Biotech has now become one of the sectors to follow this month. If you look at the Nasdaq Biotech ETF (NASDAQ:IBB), you’ll see what I mean. Kicking off the July 26th session, it hit a fresh 4-month high. The long-overdue rally comes as everything from vaccine stocks to immunotherapy companies take the spotlight heading into August. Among this long list of stocks to watch are several standouts making big breakthroughs.

While Pfizer (NYSE:PFE), BioNTech (NASDAQ:BNTX), and Moderna (NASDAQ:MRNA) fight to address the delta variant, there are other areas of biotech gaining ground and offering significant potential for savvy investors. Among the growing hoards of retail traders are those focusing solely on mobile trading.

[Read More] 3 Former Penny Stocks With Bullish Analysts & Price Targets Up To 120%

This is where you see the millions of users on Robinhood and Webull searching for the best stocks to buy on a given day. Love them or hate them, the next generation of investors has relied upon technology and social media to trade these volatile markets.

Now that broader sectors are pushing higher, this same group of traders is looking for opportunities in sectors that haven’t reached their peak yet. Falling into this category is biotech, and given the strength it has seen over the last 4 months, it may be time to start looking into companies making breakthroughs in their respective fields. Whether they were once penny stocks are long-standing industry leaders, key breakthroughs are becoming a big focus for some of these companies this week.

Top Biotech Stocks This Week

  1. GT Biopharma Inc. (NASDAQ:GTBP)
  2. Translate Bio Inc. (NASDAQ:TBIO)
  3. Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

All of these biotech stocks are actually former penny stocks. But don’t let the cheap prices early on distract from key updates recently. These updates have highlighted milestone developments from both corporate and clinical perspectives.

GT Biopharma Inc. (NASDAQ:GTBP)

Cancer research and treatment development remain an ongoing point of focus in biotech. Among the hundreds of companies working on different platforms, GT Biopharma seems to have uncovered a new generation of potential cancer treatment candidates. Built upon its tri-specific killer engager or “TriKE” platform, GT is finding new ways to attack cancer cells &, in some cases, eradicate them in certain settings (See: Small Cap Biotech Stocks Should Be On Your Watch List In 2021 & Here’s Why).

The company’s lead treatment candidate, GTB-3550, is in clinical phase trials to treat acute myeloma and myelodysplastic syndrome. So far, in its dose-escalation study,  11 patients have completed treatment in Phase 1.  According to the company, Patients 5, 7, 9, and 11 experienced 33%, 61%, 63% and 50% reduction in CD33+ AML/MDS bone marrow blast levels, respectively. 

In addition to this, to date, GT still has yet to see one patient experienced an adverse event even at the highest dose levels in this cohort, according to CEO Anthony Cataldo. This is not frequently seen in most of the standard treatments currently on the market in commercial form.

These next few weeks could be in focus for the market. One of the main reasons is that the Phase 1 safety portion of this trial is expected to finish up in late August, with published data expected by the end of September. Considering the early progress and near-term potential catalysts, GTBP stock has found itself on watch lists this year. Since the start of 2021, shares are up nearly 70% so far.

Translate Bio Inc. (NASDAQ:TBIO)

Believe it or not, Translate Bio was a former penny stock as well. Back in 2019, TBIO was trading below $5. Though that was the case, this shows the rapid growth that biotech companies can see upon continued progress in their pipeline developments. Specific to Translate, the company works on mRNA therapeutics, mainly in pulmonary diseases. Its lead mRNA program is currently under development for treating cystic fibrosis and is in a Phase 1/2 clinical trial. Aside from that, its relationship with Sanofi (NASDAQ:SNY) has resulted in a growing interest in Translate’s pipeline of mRNA candidates.

The two began a Phase 1 clinical trial of an mRNA influenza vaccine back in June. This came shortly after the company reached a %50 million milestone payment under an existing influenza mRNA vaccine program with Sanofi.

[Read More] Best Penny Stocks To Buy On Bitcoin, Dogecoin Price Action? 5 To Watch

In a statement, Ronald Renaud, chief executive officer, Translate Bio explained, “We believe that mRNA technology could have several advantages for a seasonal flu application including the potential ability to demonstrate robust immune responses based on preclinical data to date, enable antigen specificity within a short timeframe from seasonal virus strain selection, and deploy agile manufacturing capacity. We look forward to evaluating the potential of these mRNA influenza vaccine candidates in this Phase 1 clinical trial.”

Sanofi has also pledged to invest 400 million euros annually in a vaccines R&D facility to advance mRNA vaccines.

top biotech stocks to watch Translate Bio Inc. TBIO stock chart

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP)

As far as Oramed is concerned, you don’t have to look too far back to see when this was a penny stock. ORMP shares started in 2021, trading around $4. Since then, the former penny stock has reached new highs of $16.63. This is a level Oramed hasn’t seen in over 5 years.

So what’s become a driving force? The company develops oral drug delivery systems. One of its core pipeline candidates, ORMD-0801, has managed to raise some attention in the market. According to Oramed, this is positions to be the world’s first oral insulin capsule. Furthermore, to support this, the company’s current Phase 3 studies are on pace to complete enrollment before the end of the year.

In addition to this, the company is also undergoing clinical trials for an oral COVID-19 vaccine through its Oravax Medical Inc. venture. These are slated to begin during the second half of the year. To this point, last week, the company announced that clinical trials were starting, first in Israel. The Institutional Review Board in Israel approved the study protocol and is now pending approval from the Israeli Ministry of Health. 

“Our vaccine is a particularly strong candidate against the evolving COVID-19 virus due to its unique targeting of three proteins rather than one. With the Delta and other variants proving a challenge to health administrators globally, Oravax’s VLP technology could prove even more important in the effort to combat COVID,” said Nadav Kidron, CEO of Oramed.

top biotech stocks to watch Oramed Pharmaceuticals ORMP stock chart

Biotech Stocks Are Heating Up In 2021

Whether we’re talking about current or former penny stocks, the goals are the same. Finding early opportunities in emerging companies is important. While the risks are high that clinical trials can fail, other rewards exist for companies that meet or exceed expectations. In this case, it’s important to focus on early trial progress. Monitor key milestone events that demonstrate long-term potential in a company’s pipeline. With so many new treatment platforms under development, there’s plenty to watch when it comes to biotech right now.

best small cap penny stocks to watch right now biotech

Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP) Midam has been paid $150,000 for a period from March 1, 2021, to April 1, 2021. This compensation is payment 1 of 12 as part of a 12-month agreement between Midam Ventures LLC & GT Biopharma (GTBP), for a period from March 1, 2021, to February 28, 2022. Midam Ventures LLC expects to be paid $150,000 per month for a total of 12 months by GT Biopharma (GTBP). Midam has been paid an additional $150,000 for a period from April 2, 2021, to May 1, 2021. This compensation is payment 2 of 12 as part of the Agreement. Midam has been paid an additional $150,000 for a period from May 2, 2021, to June 1, 2021. This compensation is payment 3 of 12 as part of the Agreement. Midam has been paid an additional $150,000 for a period from June 2, 2021, to July 1, 2021. This compensation is payment 4 of 12 as part of the Agreement. Midam has been paid an additional $200,000 for a period from July 2, 2021, to August 2, 2021. This compensation is payment 5 of 12 as part of the Agreement. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during, or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP). Click Here For Full Disclaimer

The post Top Biotech Penny Stocks On Robinhood To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Read More

Continue Reading

Government

Mike Pompeo Doesn’t Rule Out Serving In 2nd Trump Administration

Mike Pompeo Doesn’t Rule Out Serving In 2nd Trump Administration

Authored by Jack Phillips via The Epoch Times (emphasis ours),

Former Secretary…

Published

on

Mike Pompeo Doesn't Rule Out Serving In 2nd Trump Administration

Authored by Jack Phillips via The Epoch Times (emphasis ours),

Former Secretary of State Mike Pompeo said in a new interview that he’s not ruling out accepting a White House position if former President Donald Trump is reelected in November.

“If I get a chance to serve and think that I can make a difference ... I’m almost certainly going to say yes to that opportunity to try and deliver on behalf of the American people,” he told Fox News, when asked during a interview if he would work for President Trump again.

I’m confident President Trump will be looking for people who will faithfully execute what it is he asked them to do,” Mr. Pompeo said during the interview, which aired on March 8. “I think as a president, you should always want that from everyone.”

Then-President Donald Trump (C), then- Secretary of State Mike Pompeo (L), and then-Vice President Mike Pence, take a question during the daily briefing on the novel coronavirus at the White House in Washington on April 8, 2020. (Mandel Ngan/AFP via Getty Images)

He said that as a former secretary of state, “I certainly wanted my team to do what I was asking them to do and was enormously frustrated when I found that I couldn’t get them to do that.”

Mr. Pompeo, a former U.S. representative from Kansas, served as Central Intelligence Agency (CIA) director in the Trump administration from 2017 to 2018 before he was secretary of state from 2018 to 2021. After he left office, there was speculation that he could mount a Republican presidential bid in 2024, but announced that he wouldn’t be running.

President Trump hasn’t publicly commented about Mr. Pompeo’s remarks.

In 2023, amid speculation that he would make a run for the White House, Mr. Pompeo took a swipe at his former boss, telling Fox News at the time that “the Trump administration spent $6 trillion more than it took in, adding to the deficit.”

“That’s never the right direction for the country,” he said.

In a public appearance last year, Mr. Pompeo also appeared to take a shot at the 45th president by criticizing “celebrity leaders” when urging GOP voters to choose ahead of the 2024 election.

2024 Race

Mr. Pompeo’s interview comes as the former president was named the “presumptive nominee” by the Republican National Committee (RNC) last week after his last major Republican challenger, former South Carolina Gov. Nikki Haley, dropped out of the 2024 race after failing to secure enough delegates. President Trump won 14 out of 15 states on Super Tuesday, with only Vermont—which notably has an open primary—going for Ms. Haley, who served as President Trump’s U.S. ambassador to the United Nations.

On March 8, the RNC held a meeting in Houston during which committee members voted in favor of President Trump’s nomination.

“Congratulations to President Donald J. Trump on his huge primary victory!” the organization said in a statement last week. “I’d also like to congratulate Nikki Haley for running a hard-fought campaign and becoming the first woman to win a Republican presidential contest.”

Earlier this year, the former president criticized the idea of being named the presumptive nominee after reports suggested that the RNC would do so before the Super Tuesday contests and while Ms. Haley was still in the race.

Also on March 8, the RNC voted to name Trump-endorsed officials to head the organization. Michael Whatley, a North Carolina Republican, was elected the party’s new national chairman in a vote in Houston, and Lara Trump, the former president’s daughter-in-law, was voted in as co-chair.

“The RNC is going to be the vanguard of a movement that will work tirelessly every single day to elect our nominee, Donald J. Trump, as the 47th President of the United States,” Mr. Whatley told RNC members in a speech after being elected, replacing former chair Ronna McDaniel. Ms. Trump is expected to focus largely on fundraising and media appearances.

President Trump hasn’t signaled whom he would appoint to various federal agencies if he’s reelected in November. He also hasn’t said who his pick for a running mate would be, but has offered several suggestions in recent interviews.

In various interviews, the former president has mentioned Sen. Tim Scott (R-S.C.), Texas Gov. Greg Abbott, Rep. Elise Stefanik (R-N.Y.), Vivek Ramaswamy, Florida Gov. Ron DeSantis, and South Dakota Gov. Kristi Noem, among others.

Tyler Durden Wed, 03/13/2024 - 17:00

Read More

Continue Reading

International

Riley Gaines Explains How Women’s Sports Are Rigged To Promote The Trans Agenda

Riley Gaines Explains How Women’s Sports Are Rigged To Promote The Trans Agenda

Is there a light forming when it comes to the long, dark and…

Published

on

Riley Gaines Explains How Women's Sports Are Rigged To Promote The Trans Agenda

Is there a light forming when it comes to the long, dark and bewildering tunnel of social justice cultism?  Global events have been so frenetic that many people might not remember, but only a couple years ago Big Tech companies and numerous governments were openly aligned in favor of mass censorship.  Not just to prevent the public from investigating the facts surrounding the pandemic farce, but to silence anyone questioning the validity of woke concepts like trans ideology. 

From 2020-2022 was the closest the west has come in a long time to a complete erasure of freedom of speech.  Even today there are still countries and Europe and places like Canada or Australia that are charging forward with draconian speech laws.  The phrase "radical speech" is starting to circulate within pro-censorship circles in reference to any platform where people are allowed to talk critically.  What is radical speech?  Basically, it's any discussion that runs contrary to the beliefs of the political left.

Open hatred of moderate or conservative ideals is perfectly acceptable, but don't ever shine a negative light on woke activism, or you might be a terrorist.

Riley Gaines has experienced this double standard first hand.  She was even assaulted and taken hostage at an event in 2023 at San Francisco State University when leftists protester tried to trap her in a room and demanded she "pay them to let her go."  Campus police allegedly witnessed the incident but charges were never filed and surveillance footage from the college was never released.  

It's probably the last thing a champion female swimmer ever expects, but her head-on collision with the trans movement and the institutional conspiracy to push it on the public forced her to become a counter-culture voice of reason rather than just an athlete.

For years the independent media argued that no matter how much we expose the insanity of men posing as women to compete and dominate women's sports, nothing will really change until the real female athletes speak up and fight back.  Riley Gaines and those like her represent that necessary rebellion and a desperately needed return to common sense and reason.

In a recent interview on the Joe Rogan Podcast, Gaines related some interesting information on the inner workings of the NCAA and the subversive schemes surrounding trans athletes.  Not only were women participants essentially strong-armed by colleges and officials into quietly going along with the program, there was also a concerted propaganda effort.  Competition ceremonies were rigged as vehicles for promoting trans athletes over everyone else. 

The bottom line?  The competitions didn't matter.  The real women and their achievements didn't matter.  The only thing that mattered to officials were the photo ops; dudes pretending to be chicks posing with awards for the gushing corporate media.  The agenda took precedence.

Lia Thomas, formerly known as William Thomas, was more than an activist invading female sports, he was also apparently a science project fostered and protected by the athletic establishment.  It's important to understand that the political left does not care about female athletes.  They do not care about women's sports.  They don't care about the integrity of the environments they co-opt.  Their only goal is to identify viable platforms with social impact and take control of them.  Women's sports are seen as a vehicle for public indoctrination, nothing more.

The reasons why they covet women's sports are varied, but a primary motive is the desire to assert the fallacy that men and women are "the same" psychologically as well as physically.  They want the deconstruction of biological sex and identity as nothing more than "social constructs" subject to personal preference.  If they can destroy what it means to be a man or a woman, they can destroy the very foundations of relationships, families and even procreation.  

For now it seems as though the trans agenda is hitting a wall with much of the public aware of it and less afraid to criticize it.  Social media companies might be able to silence some people, but they can't silence everyone.  However, there is still a significant threat as the movement continues to target children through the public education system and women's sports are not out of the woods yet.   

The ultimate solution is for women athletes around the world to organize and widely refuse to participate in any competitions in which biological men are allowed.  The only way to save women's sports is for women to be willing to end them, at least until institutions that put doctrine ahead of logic are made irrelevant.          

Tyler Durden Wed, 03/13/2024 - 17:20

Read More

Continue Reading

Uncategorized

Part 1: Current State of the Housing Market; Overview for mid-March 2024

Today, in the Calculated Risk Real Estate Newsletter: Part 1: Current State of the Housing Market; Overview for mid-March 2024
A brief excerpt: This 2-part overview for mid-March provides a snapshot of the current housing market.

I always like to star…

Published

on

Today, in the Calculated Risk Real Estate Newsletter: Part 1: Current State of the Housing Market; Overview for mid-March 2024

A brief excerpt:
This 2-part overview for mid-March provides a snapshot of the current housing market.

I always like to start with inventory, since inventory usually tells the tale!
...
Here is a graph of new listing from Realtor.com’s February 2024 Monthly Housing Market Trends Report showing new listings were up 11.3% year-over-year in February. This is still well below pre-pandemic levels. From Realtor.com:

However, providing a boost to overall inventory, sellers turned out in higher numbers this February as newly listed homes were 11.3% above last year’s levels. This marked the fourth month of increasing listing activity after a 17-month streak of decline.
Note the seasonality for new listings. December and January are seasonally the weakest months of the year for new listings, followed by February and November. New listings will be up year-over-year in 2024, but we will have to wait for the March and April data to see how close new listings are to normal levels.

There are always people that need to sell due to the so-called 3 D’s: Death, Divorce, and Disease. Also, in certain times, some homeowners will need to sell due to unemployment or excessive debt (neither is much of an issue right now).

And there are homeowners who want to sell for a number of reasons: upsizing (more babies), downsizing, moving for a new job, or moving to a nicer home or location (move-up buyers). It is some of the “want to sell” group that has been locked in with the golden handcuffs over the last couple of years, since it is financially difficult to move when your current mortgage rate is around 3%, and your new mortgage rate will be in the 6 1/2% to 7% range.

But time is a factor for this “want to sell” group, and eventually some of them will take the plunge. That is probably why we are seeing more new listings now.
There is much more in the article.

Read More

Continue Reading

Trending